Considering this critically important role of the NO/sGC/cGMP in the cardiorenal physiology and pathophysiology, targeting this pathway is currently considered as one of the most promising approaches to HFrEF treatment [77, 80, 81] and could have a large potential also for the treatment of chemotherapy-induced HF. This evidence concerns the gene SGCB and hydrops fetalis.